Bautista-Peñalosa Patricia A, M Estrada Francis Gerard, Barrenechea Emerita A, San Luis Teofilo O L
St. Luke's Medical Center - Global City, Philippines.
Our Lady of Mt. Carmel Medical Center, Pampanga, Philippines.
Asia Ocean J Nucl Med Biol. 2024;12(1):69-72. doi: 10.22038/AOJNMB.2023.72838.1508.
Barriers to the establishment of advanced technologies in developing countries were overcome when modern theranostics pertaining to the use of Ga-68 and Lu-177 PSMA and DOTATATE were first offered to patients in the Philippines in early 2018. However, significant growth was not experienced at St. Luke's Medical Center for five years and lutetium was not yet distributed to other institutions by a radiopharmaceutical supplier. Due to the relative novelty and rapid expansion of theranostics worldwide, position statements were released by the Australasian Association of Nuclear Medicine Specialists, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and International Atomic Energy Agency primarily to uphold patient safety and ensure a level of standard among its practitioners. Subsequently in the latter half of 2022, these were adopted and modified according to what is feasible and applicable locally within the Philippine Society of Nuclear Medicine, considering the current status and future possibilities. Different representatives were involved, and several groups were mobilized for successful implementation. A liability clause was incorporated to discourage unprofessional acts.
2018年初，当与使用镓-68、镥-177 PSMA和DOTATATE相关的现代诊疗技术首次在菲律宾提供给患者时，发展中国家建立先进技术的障碍被克服了。然而，圣卢克医疗中心在五年内并未实现显著增长，并且放射性药物供应商尚未将镥分发给其他机构。由于诊疗技术在全球范围内相对新颖且发展迅速，澳大利亚核医学专家协会、欧洲核医学协会、核医学与分子成像协会以及国际原子能机构发布了立场声明，主要是为了维护患者安全并确保从业者的一定标准水平。随后在2022年下半年，菲律宾核医学协会根据当地可行和适用的情况对这些声明进行了采纳和修改，同时考虑了当前状况和未来可能性。不同的代表参与其中，为成功实施动员了几个团体。纳入了责任条款以防止不专业行为。
